New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...

Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study ...

- Investor conference call and webcast to discuss data and clinical trial plans on June 2, 2025, at 7:00 a.m. CT / 8:00 a.m. ET / 8:00 p.m. HKT SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / ...